End of story as Guidant concedes to $4bn cut in Johnson & Johnson offer?
This article was originally published in Clinica
Executive Summary
Just as investors were preparing for a messy courtroom battle between Guidant and Johnson & Johnson, the two companies declared a truce and have laid down their arms. J&J announced on November 15 that the firms have agreed on a revised deal whereby it will acquire Guidant for $21.5bn - almost $4bn less than the original $25.4bn offer.
You may also be interested in...
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.